Manipal Health Enterprises opens Rs 9,275 crore IPO at Rs 560-590 band

The Development

Manipal Health Enterprises Limited, which operates the Manipal Hospitals network, has opened public subscription for its initial public offering, an issue valued at about Rs 9,275 crore at the top of its price band. Per the red herring prospectus (RHP) dated 23 July 2026 and filed with the Securities and Exchange Board of India (SEBI), the offer combines a fresh issue of equity shares aggregating up to Rs 8,000 crore with an offer for sale of up to 21,613,834 shares by existing shareholders. The company fixed the price band at Rs 560 to Rs 590 per equity share of face value Rs 2.

Per the RHP timetable, anchor investor bidding took place on 28 July 2026, the offer opened for public subscription on 29 July and closes on 31 July 2026. The equity shares are proposed to be listed on both the BSE and the National Stock Exchange (NSE), with the NSE designated as the stock exchange for the offer.

As of the close of the first day on 29 July, per NSE bid data (updated as on 29 July 2026, 5:00 pm), the issue had been subscribed about 0.12 times overall, with the qualified institutional buyer portion at 0.12 times, the non-institutional portion at 0.06 times and the retail portion at 0.19 times. The development was surfaced via markets coverage in The Economic Times.

The Company

Per the RHP, Manipal Health Enterprises runs a pan-India network of multispecialty hospitals and describes itself as "the largest pan-India multispecialty hospital network by bed capacity" as of 31 March 2026, citing a CRISIL report. As of that date the company disclosed 49 hospitals, including six run under operations-and-management deals, with 13,037 licensed beds across 14 states and union territories. It served 7.63 million patients in Fiscal 2026, per the RHP. Its clinical focus is on tertiary and quaternary care across cardiac sciences, oncology, neurosciences, gastro sciences, orthopedics and renal sciences, a grouping it labels CONGO-R.

The promoters include Dr. Ranjan Ramdas Pai and several investment holding entities, and Dilip Jose Puthiyidathu is the managing director and chief executive. On financials, the company discloses restated consolidated total income of Rs 10,520.5 crore in Fiscal 2026, up from Rs 8,362.8 crore in Fiscal 2025 and Rs 6,265.2 crore in Fiscal 2024. Profit for the year was Rs 916.5 crore in Fiscal 2026, lower than the Rs 1,081.7 crore of Fiscal 2025 and above the Rs 533.2 crore of Fiscal 2024, per the RHP. The offer document also discloses total borrowings of Rs 10,553.4 crore as of 31 March 2026 and an occupancy rate of 64.47% for the year.

The Offer Structure

Per the RHP, the fresh issue is sized at up to Rs 8,000 crore, while the offer for sale covers up to 21,613,834 shares; at the Rs 590 cap price that sale portion is worth roughly Rs 1,275 crore, taking the total offer to about Rs 9,275 crore. Selling shareholders in the offer for sale include the promoter entity Imperius Healthcare Investments Pte. Ltd. (up to 10,808,861 shares) and promoter group entity Manipal Education and Medical Group India Private Limited (up to 6,792,002 shares), alongside investor shareholders TPG SG Magazine Pte. Ltd., Seventy Second Investment Company LLC, Ammar Sdn Bhd, Novo Holdings Invest Asia A/S and Phoenix Bear Investments, LLC.

The stated objects of the fresh issue, per the RHP, are the repayment or prepayment of certain borrowings of its material subsidiary Manipal Hospitals Private Limited (up to Rs 5,552.8 crore) and the acquisition of a minority stake in its stepdown subsidiary Sahyadri Hospitals Private Limited (up to Rs 574 crore), with the balance for general corporate purposes. The company will not receive any proceeds from the offer for sale. The book-running lead managers are Kotak Mahindra Capital, Axis Capital, Goldman Sachs (India) Securities, Jefferies India, J.P. Morgan India, UBS Securities India and DBS Bank India, and KFin Technologies is the registrar. Applications in the retail category are made in lots as fixed in the price band advertisement. Readers working through the arithmetic of an allotment may use Oquilia's lumpsum calculator or CAGR calculator; prior coverage sits on the news desk.

Risk Factors

The RHP sets out its risk factors, several of which concern concentration. The company discloses that it derived 46.40% of its revenue from operations in Fiscal 2026 from its hospitals in Karnataka, and warns that disruption there "could have a material adverse effect" on its business. It also flags its reliance on inpatient care, noting that any inability to maintain admissions and occupancy rates could hurt its results.

The RHP lists concentration in the CONGO-R specialties, which accounted for 64.30% of gross inpatient revenue in Fiscal 2026, and a reliance on insurance companies and third-party administrators, which contributed 49.68% of gross inpatient revenue that year. The company further discloses exposure to legal claims and regulatory actions "arising out of alleged medical negligence". The offer document also states that the offer is being made under Regulation 6(2) of the SEBI ICDR Regulations because the company had net tangible assets of less than Rs 3 crore in Fiscal 2026, and that share transfers in the preceding twelve months may have been at prices lower than the offer price.

What Happens Next

With anchor allocation completed on 28 July and the three-day subscription window running from 29 to 31 July 2026, bids are collected across the qualified institutional, non-institutional, retail and employee categories through the exchange platforms and the UPI and ASBA blocking mechanism. Per the offer schedule, the basis of allotment is expected to be finalised on or about 3 August, with refunds and the unblocking of application amounts to follow, and listing on the BSE and NSE anticipated on or about 5 August 2026.

SEBI's role in the process is limited. The RHP carries SEBI's standard disclaimer that the shares "have neither been recommended, nor approved" by the regulator and that SEBI does not guarantee the accuracy of the document. The final offer price will be set through the book-building process and confirmed in the prospectus filed with the Registrar of Companies.

FAQ

What is the price band and lot size?

Per the RHP and NSE, the price band is Rs 560 to Rs 590 per equity share of face value Rs 2. Retail applications are made in lots, with the bid lot fixed in the price band advertisement.

When does the issue open and close?

Per the RHP, anchor bidding was on 28 July 2026, the offer opened on 29 July and closes on 31 July 2026, with the UPI mandate cut-off at 5:00 pm on the closing day. Listing on the BSE and NSE is scheduled to follow.

What are the objects of the offer?

Per the RHP, the fresh issue proceeds are earmarked for repaying certain borrowings of subsidiary Manipal Hospitals Private Limited and for acquiring a minority stake in stepdown subsidiary Sahyadri Hospitals Private Limited, with the remainder for general corporate purposes. The company receives nothing from the offer-for-sale portion.

What do SEBI's observations mean?

SEBI processing a draft offer document and the company then filing its RHP allow the issue to proceed, but this is not an endorsement. The RHP states that the shares have neither been recommended nor approved by SEBI, which does not vouch for the merits of the offer.

Should I apply for this IPO?

Oquilia does not make recommendations. This report is informational and is not investment advice or a recommendation to subscribe. The RHP, including the complete risk-factors section, is available on SEBI's website and the exchanges - read it directly before making any decision.

This report is based on the red herring prospectus filed with SEBI and issue and bid data from the NSE. It was surfaced via coverage in The Economic Times.